Hara Capital LLC Increases Position in Sanofi (NASDAQ:SNY)

Hara Capital LLC increased its stake in Sanofi (NASDAQ:SNY) by 16.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,888 shares of the company’s stock after purchasing an additional 680 shares during the quarter. Hara Capital LLC’s holdings in Sanofi were worth $236,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SNY. Creative Planning grew its stake in Sanofi by 18.0% in the 3rd quarter. Creative Planning now owns 220,763 shares of the company’s stock valued at $12,723,000 after acquiring an additional 33,728 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Sanofi by 15.2% during the 3rd quarter. Global Retirement Partners LLC now owns 6,315 shares of the company’s stock worth $364,000 after purchasing an additional 834 shares during the last quarter. Net Worth Advisory Group acquired a new stake in shares of Sanofi during the 3rd quarter worth about $297,000. Blue Trust Inc. boosted its stake in shares of Sanofi by 31.7% during the 3rd quarter. Blue Trust Inc. now owns 18,046 shares of the company’s stock worth $1,040,000 after purchasing an additional 4,346 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Sanofi by 434.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 50,583 shares of the company’s stock worth $2,915,000 after purchasing an additional 41,117 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

Sanofi stock opened at $54.50 on Tuesday. The company has a market cap of $138.31 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The stock’s 50-day moving average is $50.42 and its 200-day moving average is $52.47.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.